Le Pure Bio is a company engaged in single-use products and leak detection equipment in the biotechnology and pharmaceutical industries. The company develops and produces single-use biopharmaceutical process equipment and consumables. The products are used for the storage, transfer, filling and leak detection of various samples in the process of biosimilars, vaccines and other biopharmaceuticals. The core product is a disposable liquid storage bag. Lechun Biotech recently received several hundred million yuan in Series C financing, led by institutions such as Novo Nordisk’s controlling shareholder Novo Holdings (Novo Holdings), General Atlantic Investment Group (General Atlantic), Goldman Sachs Asset Management (Goldman Sachs), and old shareholders Honghui Fund, Kangjun Capital, Huimei Capital, China Science and Technology Innovation, Huaying Health Fund, etc. followed the investment. This round of financing will be mainly used for the construction of R&D centers in China and the United States, talent recruitment, overseas business expansion, and high-quality mergers and acquisitions at home and abroad.
This article is transferred from: https://www.itjuzi.com/investevent/13770992
This site is only for collection, and the copyright belongs to the original author.